| Attending joint formulation meetings on pharmaceuticals and special medical materials. | Cancer
> Cancer: de flesta typer | Regulatoriskt partnerskap
> Arbeta med tillsynsmyndigheter | 100 000 | National | Sometimes | 119017792133 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance] reimbursement policies for that year. | Cancer
> Cancer: de flesta typer | Regulatoriskt partnerskap
> Arbeta med tillsynsmyndigheter | 5 000 | National | Sometimes | 119022421395 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Cancer
> Cancer: de flesta typer | Regulatoriskt partnerskap
> Delta i utvärderingar av medicinsk teknik (HTA) och ersättningsgranskningar | 5 000 | National | Sometimes | 119022421395 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromuskulär
> Spinal muskelatrofi (SMA) | Regulatoriskt partnerskap
> Delta i utvärderingar av medicinsk teknik (HTA) och ersättningsgranskningar | 100 | National | Regularly | 119053648739 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Cancer
> Cancer: de flesta typer | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | 5 000 | National | Sometimes | 119022421395 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance/Taiwan] reimbursement policies for that year. | Cancer
> Cancer: de flesta typer | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | 5 000 | National | Sometimes | 119022421395 |
| ... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome. | Cancer
> Cancer: de flesta typer | Påverka politik och lagstiftning
> Påverka hälso- och sjukvårdspolitik och lagstiftning | 10 000 | National | Sometimes | 119055308347 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Cancer
> Cancer: de flesta typer | Påverka politik och lagstiftning
> Delta i offentliga utfrågningar och samråd | 10 000 | National | Sometimes | 119055325391 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Allmän hälsa
> Sjukvårdsutförande | Påverkansarbete för prissättning och prisvärdhet
> Förespråka rättvisa läkemedelspriser | 5 000 | National | Sometimes | 119051396882 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Cancer
> Cancer: bröst | Påverkansarbete för prissättning och prisvärdhet
> Förespråkar inkludering av produkten i ersättningslistor/nationella läkemedelsförteckningar | 10 000 | National | Regularly | 119016883314 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Allmän hälsa
> Sjukvårdsutförande | Påverkansarbete för prissättning och prisvärdhet
> Förespråkar inkludering av produkten i ersättningslistor/nationella läkemedelsförteckningar | 5 000 | National | Sometimes | 119051396882 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Cancer
> Cancer: neuroendokrin (NET) | Påverkansarbete för prissättning och prisvärdhet
> Förespråkar inkludering av produkten i ersättningslistor/nationella läkemedelsförteckningar | 100 | National | Sometimes | 119051407743 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Cancer
> Cancer: de flesta typer | Påverkansarbete för prissättning och prisvärdhet
> Förespråkar inkludering av produkten i ersättningslistor/nationella läkemedelsförteckningar | 10 000 | National | Sometimes | 119055325391 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Cancer
> Cancer: bröst | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | 10 000 | National | Regularly | 119016883314 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Cancer
> Cancer: neuroendokrin (NET) | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | 100 | National | Sometimes | 119051407743 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromuskulär
> Spinal muskelatrofi (SMA) | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | 100 | National | Regularly | 119053648739 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Cancer
> Cancer: de flesta typer | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | 10 000 | National | Sometimes | 119055308347 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Cancer
> Cancer: de flesta typer | Evidensbaserat patientinput
> Använd patientinsikter för att informera beslut | 5 000 | National | Sometimes | 119022421395 |
| We serve as members of the Infected Persons Rights Protection Committee under Taiwan CDC [Centers for Disease Control]. | HIV
> HIV | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | 5 000 | National | Regularly | 119021698989 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Cancer
> Cancer: de flesta typer | Institutionell styrning
> Arbeta effektivt inom nätverk med flera intressenter | 10 000 | National | Sometimes | 119055308347 |
interaktioner
åtgärder & påverkansarbete
5 omnämnanden
